A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment.
CV comorbidities or complications are a major problem for breast cancer survivors. Survivors are at an increased risk for CV disease, and so the authors looked at whether or not the use of a weight ...